Perspective Therapeutics, Inc. Corporate Presentation Update
Perspective Therapeutics, Inc. has updated its corporate presentation on October 1, 2026. The presentation details the company's advancements in next-generation radiopharmaceuticals for targeted oncology, focusing on three clinical-stage programs: VMT-Ξ±-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for advanced solid tumors. The company highlights the potential of its 212Pb-based therapies, emphasizing their "best-in-class" profiles, durable disease control, and potential for broad therapeutic windows. The presentation also covers the company's integrated platform, manufacturing capabilities, strong intellectual property portfolio, and the significant market opportunity in targeted oncology, which is estimated at over $45 billion. Perspective Therapeutics aims to redefine targeted oncology by optimizing the entire system for delivering potent payloads directly to tumors, with a strategy that includes regional manufacturing for on-demand delivery and potential combination therapies.